Knowledge about the etiology and diagnosis as well as treatment concepts of neu- oncologic diseases is rapidly growing. This turnover of knowledge makes it dif? cult for the physician engaged in the treatment to keep up to date with current therapies. This book sets out to close the gap and pursues several innovative concepts. As a comprehensive text on neuro-oncology, its chapters are interconnected, but at the same time some chapters or subdivisions are so thoroughly assembled that the whole volume gives the impression of several books combined into one. Neuropathology is treated in an extensive and clearly structured section. The int- ested reader ? nds for each tumor entity the latest well-referenced consensus rega- ing histologic and molecular pathology. Through this “book-in-the-book” concept, information on neuropathology is readily at hand in a concise form and without ov- loading the single chapters. Pediatric neuro-oncology differs in many entities from tumors in adult patients; also, certain tumors of the CNS are typically or mainly found only in the child. Therefore, pediatric neuro-oncology was granted its own, book-like section. Tumor entities that are treated differently in children and adults are included both in the pediatric neuro-oncology section and in the general section. Entities that typically occur only in the child and adolescent are found in the pediatric section in order to avoid redundancies.

Knowledge about the etiology and diagnosis as well as treatment concepts of neu- oncologic diseases is rapidly growing. This turnover of knowledge makes it dif? cult for the physician engaged in the treatment to keep up to date with current therapies. This book sets out to close the gap and pursues several innovative concepts. As a comprehensive text on neuro-oncology, its chapters are interconnected, but at the same time some chapters or subdivisions are so thoroughly assembled that the whole volume gives the impression of several books combined into one. Neuropathology is treated in an extensive and clearly structured section. The int- ested reader ? nds for each tumor entity the latest well-referenced consensus rega- ing histologic and molecular pathology. Through this “book-in-the-book” concept, information on neuropathology is readily at hand in a concise form and without ov- loading the single chapters. Pediatric neuro-oncology differs in many entities from tumors in adult patients; also, certain tumors of the CNS are typically or mainly found only in the child. Therefore, pediatric neuro-oncology was granted its own, book-like section. Tumor entities that are treated differently in children and adults are included both in the pediatric neuro-oncology section and in the general section. Entities that typically occur only in the child and adolescent are found in the pediatric section in order to avoid redundancies.

****When not purchasing directly from the official sales agents of the WHO, especially at online bookshops, please note that there have been issues with counterfeited copies. Buy only from known sellers and if there are quality issues, please contact the seller for a refund.***** The WHO Classification of Tumours Central Nervous System Tumours is the sixth volume in the 5th edition of the WHO series on the classification of human tumors. This series (also known as the WHO Blue Books) is regarded as the gold standard for the diagnosis of tumors and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. These authoritative and concise reference books provide indispensable international standards for anyone involved in the care of patients with cancer or in cancer research, underpinning individual patient treatment as well as research into all aspects of cancer causation, prevention, therapy, and education. What's new in this edition? The 5th edition, guided by the WHO Classification of Tumours Editorial Board, will establish a single coherent cancer classification presented across a collection of individual volumes organized on the basis of anatomical site (digestive system, breast, soft tissue and bone, etc.) and structured in a systematic manner, with each tumor type listed within a taxonomic classification: site, category, family (class), type, and subtype. In each volume, the entities are now listed from benign to malignant and are described under an updated set of headings, including histopathology, diagnostic molecular pathology, staging, and easy-to-read essential and desirable diagnostic criteria. Who should read this book? Pathologists Neuro-oncologists Neuroradiologists Medical oncologists Radiation oncologists Neurosurgeons Oncology nurses Cancer researchers Epidemiologists Cancer registrars This volume Prepared by 199 authors and editors Contributors from around the world More than 1100 high-quality images More than 3600 references WHO Classification of Tumours Online The content of this renowned classification series is now also available in a convenient digital format by purchasing a subscription directly from IARC here.

This book elucidates the radiation therapy protocols and procedures for the management of adult patients presenting with primary benign and malignant central nervous system tumors. With the development of new treatment strategies and rapid advancement of radiation technology, it is crucial for radiation oncologists to maintain and refine their knowledge and skills. Dedicated exclusively to adult CNS radiation oncology, this textbook explores CNS tumors ranging from the common to the esoteric as well as secondary cancers of metastatic origin. The first half of the book is organized anatomically: tumors of the brain, spinal cord, leptomeninges, optic pathway, ocular choroid, and skull base. The second half covers primary CNS lymphoma, rare CNS tumors, metastatic brain disease, vascular conditions of the CNS, radiation-associated complications, and radiation modalities. Each chapter provides guidance on treatment field design, target delineation, and normal critical structure tolerance constraints in the context of the disease being treated. Learning objectives, case studies, and Maintenance of Certification Self-Assessment Continuing Medical Education-style questions and answers are incorporated throughout the book. This is an ideal guide for radiation oncologists, residents, and fellows, but medical students may also find value in the text.

Cancers of the central nervous system are among the most lethal of human neoplasms. They are recalcitrant to even intensive multimodality therapies that include surgery, radiotherapy, and chemotherapy. Moreover, especially in children, the consequences of these therapies can itself be devastating and involve serious cognitive and developmental disorders. It is small wonder that such cancers have come under the intense scrutiny of each of the subspecialties of clinical care and investigation as well as attracting some of the best basic research scientists. Their joint efforts are gradually peeling away the mysteries surrounding the genesis and progression of these tumors and inroads are being steadily made into understanding why they resist therapies. This makes it an especially opportune time to assemble some of the best investigators in the field to review the ‘‘state of the art’’ in the various arenas that comprise the assault on CNS tumors. The breadth of this effort by the clinical and basic neuro-oncology community is quite simply amazing. To a large extent, it evolves from the knowledge of the human genome and its regulation that has been hard won over the past two decades.

Thoroughly revised to reflect the latest advances in neurosurgery, radiation oncology, chemotherapy, biological therapy, and the basic sciences, the Second Edition of this highly acclaimed volume is the most comprehensive, current reference on tumors of the central and peripheral nervous system. More than 100 of the foremost authorities present multimodality treatment strategies for specific tumor types and examine the mechanisms of tumorigenesis. Coverage includes state-of-the-art information on image-guided surgery, local delivery systems, intraoperative imaging, proton beam therapy, conformal systems, radiosurgery, new drugs and biological agents, and cell cycle deregulation and chromosomal abnormalities in tumorigenesis. This edition contains over 400 illustrations.

Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas.